logo

For the Inventor, By the Inventor

Gwynedd Valley, PA, United States of America

Joel R Huff

This inventor holds 22 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: Merck + Co., Inc.. Active years: 1978-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joel R Huff. Retrieved from https://idiyas.com/inventor/joel-r-huff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 133(Granted Patents)


Location History:

  • Lansdale, PA (US) (1978 - 1979)
  • Gwynedd, PA (US) (1981 - 1983)
  • Lederach, PA (US) (1985 - 1990)
  • Gwynedd Valley, PA (US) (1996 - 1998)

Company Filing History:

goldMedal22 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1978-1998

Loading Chart...
Areas of Expertise:
HIV Protease Inhibitors
Alpha Adrenergic Antagonists
Reverse Transcriptase Inhibitors
Neoplastic Disease Treatments
Hexahydroarylquinolizines
Spiro Compounds
Piperazinyl Compounds
Analgesic Derivatives
N-Carboxyl Amino Acids
Imidazoles
Quinolizine Sulfonamides
Pyrazines
22 patents (USPTO):Explore Patents
1. 5807841 - HIV protease inhibitors useful for the treatment of AIDS (1998-09-15),
2. 5760054 - Alpha IC adrenergic receptor antagonists (1998-06-02),
3. 5717097 - HIV protease inhibitors useful for the treatment of AIDS (1998-02-10),
4. 5646148 - HIV protease inhibitors useful for the treatment of AIDS (1997-07-08),
5. 5527819 - Inhibitors of HIV reverse transcriptase (1996-06-18),
6. 5502060 - HIV protease inhibitors (1996-03-26),
7. 5502053 - HIV protease inhibitor compounds (1996-03-26),
8. 4923878 - Quinolizine sulfonamides used against certain neoplastic disease states (1990-05-08),
9. 4916223 - Substituted hexahydroarylquinolizines (1990-04-10),
10. 4831035 - Substituted hexahydroarylquinolizines (1989-05-16),
11. 4824849 - .alpha..sub.2 -adrenoceptor antagonistic arylquinolizines (1989-04-25),
12. 4710504 - Anti-depressant spiro hexahydro arylquinolizine derivatives, (1987-12-01),
13. 4690928 - Substituted hexahydro arylquinolizines as .alpha..sub.2 blockers (1987-09-01),
14. 4686226 - Substituted benzo[b]furo- and benzo[b]thieno quinolizines (1987-08-11),
15. 4506074 - 2-[2-Pyridinyloxy(thio or amino)methyl]-1H-imidazoles and derivatives (1985-03-19),

Title: Joel R. Huff: Innovator in HIV Treatment

Introduction

Joel R. Huff, based in Gwynedd Valley, PA, is a prominent inventor known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 22 patents, Huff has made remarkable strides in the development of treatments for HIV and AIDS.

Latest Patents

Among his latest patents, one highlights the formulation of HIV protease inhibitors useful for the treatment of AIDS. These compounds, detailed as formula ##STR1##, serve as vital components in the fight against HIV infection and the management of AIDS. The patents describe various methods for preventing or treating HIV infections, emphasizing the versatility of these compounds in pharmaceutical compositions, including potential combinations with other antivirals and therapeutic agents.

Career Highlights

Joel R. Huff’s career has been marked by innovation while working at Merck & Company, Inc. His contributions have played a crucial role in advancing methods and therapies that address some of the most pressing health challenges today, particularly those related to HIV.

Collaborations

Throughout his career, Huff has collaborated with notable colleagues, including Walfred S. Saari and Joseph P. Vacca. These collaborations have enriched his research, fostering a collaborative environment that has led to groundbreaking advancements in therapeutic compounds.

Conclusion

Joel R. Huff stands out as a key figure in the pharmaceutical industry, particularly in the ongoing battle against HIV and AIDS. His innovative work and collaborations demonstrate a commitment to scientific progress, impacting the lives of many and contributing to the broader field of medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…